HER2-positive breast cancer impacts 20-30 percent of all breast cancer patients. This form of breast cancer tends to be more aggressive and impact younger women.
A recent clinical trial has shown promising results and may offer another treatment option for these patients. Phase 3 of the SOPHIA study looked at the impact of a new drug called Margetuximab.
Watch the full video below.